About CARE™
The CARE™ Faculty is recognizing its 15th year in 20/20 and plans to continue its evolving discussion on biosimilars and access to innovation with robust programming in 20/20 and beyond.
We develop education initiatives directed at our peers, nurses, pharmacists, patients, government and private payers.
LEARN MORE
Current Events
[Recent] Publications
Hematology
CARE™ Supplement:
Multiple Myeloma
The following CARE™ Supplement highlights key trial updates and data releases in the category of MM from the 2019 American Society of Hematology (ASH) annual meeting. This CARE™ Supplement focuses on daratumumab, one of the most impactful therapies on MM management in recent years.
View Publication
CARE™ at ASH happened on December 6th, 2019. It is the largest gathering of hematologists outside of Canada. CARE™ has provided a summary report and the speaker slides presentations.
View Publication
Hematology
CARE™ at ASH 2019:
Presentations & Report
Rheumatology
CARE™ Perspectives:
More Innovation Needed in Rheumatology
Select members of the CARE™ Rheumatology Faculty used the 2019 ACR conference as an opportunity to meet and discuss the impact of, and continued support for access to innovation and biosimilar adoption, specifically from a Canadian context/perspective.
View Publication
The CARE™ ACG/UEGW 2019 Conference Report highlights key news in gastroenterology with a specific focus on inflammatory bowel disease (IBD), framed from a Canadian perspective.
View Publication
Gastroenterology
CARE™ Perspectives:
ACG/UEGW 2019
CARE™ is doing a Needs Assessment on the evolving treatment landscape and recent/anticipated therapy approvals in Diffuse Large B-cell Lymphoma (DLBCL). We would greatly appreciate if you could spare a few minutes to complete our survey:
https://buff.ly/2onBBKU
Arm your high-risk patients with information about UTSW’s comprehensive #PancreaticCancer prevention program. #pancsm
https://bit.ly/2SASGhn
